|
|
|
| Clinical efficacy of ABCD regimen for relapsed/refractory multiple myeloma |
| ZHOU Hongwei ZHOU Xiaoyan WANG Zhihong LIANG Yaojie ZHOU Minhang YAO Yibing LIU Mo SUN Junzhong |
| Department of Geriatric Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China |
|
|
|
Abstract Objective To investigate the therapeutic effectiveness and side effects of ABCD regimen for relapsed/refractory multiple myeloma (MM). Methods Clinical data of 5 patients suffered from relapsed/refractory MM from November 2013 to May 2015 were analyzed retrospectively, including age, sex, peripheral blood and bone marrow characteristics and so on. These patients were treated by ABCD regimen (Epirubicin 40 mg/m2 d1, Carmustine 62.5 mg d1, Cyclophosphamide 600 mg/m2 d1, Dexamethasone 20 mg d1-4) for 3 to 6 course. The therapeutic effectiveness and side effects were evaluated. Results Among 5 patients, 1 patient was male and 4 patients were females with the age ranged from 48 years to 74 years. Their median myeloma cell ratio was 7.75%, median blood serum β2 microglobulin and albumin was 3.3 μg/L and 37.9 g/L before salvage therapy, respectively. The median course of treatment received by the series was 5. After treatment by ABCD regimen, 3 patients achieved partial remission, 1 patient achieved minimal response, 1 patient achieved stable disease. The median progression survival time was 4 months. The main side effects of treatment were grade 2 of gastrointestinal symptom (3 cases) and fatigue (3 cases), 1 case of grade 3 bone marrow and lung infection. Conclusion ABCD regimen is promising for the treatment of relapsed/refractory MM patients in terms of overall response rate and manageable adverse effects.
|
|
|
|
|
|
[1] AI-Hujaily EM，Oldham RA，Hari P，et al. Development of novel immunotherapies for multiple myeloma [J]. Int J Mol Sci，2016，17（9）：1506.
[2] Siegel RL，Miller KD，Jemal A，et al. Cancer statistics，2017 [J]. CA Cancer J Clin，2017，67（1）：7-30.
[3] Rajkumar SV，Harousseau JL，Durie B，et al. Consensus recommendations for the uniform reporting of clinical trials：report of the International Myeloma Workshop Consensus Panel 1 [J]. Blood，2011，117（18）：4691-4695.
[4] 张之南，郝玉书，赵建强，等.血液病学[M].2版.北京：人民卫生出版社，2011.
[5] Palumbo A，Rajkumar SV，San Miguel JF，et al. International Myeloma Working Group consensus statement for the management， treatment， and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation [J]. J Clin Oncol，2014，32（6）：57-60.
[6] Richardson PG，Xie W，Jaqannath S，et al. A phase 2 trial of lenalidomide，bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma [J]. Blood，2014，123（10）：1461-1469.
[7] Kumar SK，Callander NS，Alsina M，et al. NCCN Guidelines Insights：Multiple Myeloma，Version 3.2018 [J]. J Natl Compr Canc Netw，2018，16（1）：11-20.
[8] Anderson KC. The 39th David A. Karnofsky lecture：bench-to-bedside translation of targeted therapies in multiple myeloma [J]. J Clin Oncol，2012，30（4）：445-452.
[9] Barosi G，Merlini G，Billio A，et al. SIE，SIES，GITMO evidence-based guidelines on novel agents（thalidomide，bortezomib，and lenalidomide）in the treatment of multiple myeloma [J]. Ann Hematol，2012，91（6）：875-888.
[10] Kumar SK，Dimopoulos MA，Kastritis E，et al. Natural history of relapsed myeloma，refractory to immunomodulatory drugs and proteasome inhibitors：a multicenter IMWG study [J]. Leukemia，2017，31（11）：2443-2448.
[11] Botta C，Ciliberto D，Rossi M，et al. Network meta-analysis of randomized trials in multiple myeloma：efficacy and safety in relapsed/refractory patients [J]. Blood Adv，2017，1（7）：455-466.
[12] Richardson PG，Weller E，Jaqannath S，et al. Multicenter，phase I，dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma [J]. J Clin Oncol，2009，27（34）：5713-5719.
[13] Dimopoulos MA，Moreau P，Palumbo A，et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma （ENDEAVOR）：a randomised，phase 3，open-label，multicentre study [J]. Lancet Oncol，2016，17（1）：27-38.
[14] Dimopoulos MA，Goldschmidt H，Niesvizky R，et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma（ENDEAVOR）：an interim overall survival analysis of an open-label，randomised，phase 3 trial [J]. Lancet Oncol，2017，18（10）：1327-1337.
[15] Siegel DS，Dimopoulos MA，Ludwig H，et al. Improvement in overall survival with Carfilzomib，lenalidomide，and dexamethasone in patients with relapsed or refractory multiple myeloma [J]. J Clin Oncol，2018，36（8）：728-734.
[16] Moreau P，Masszi T，Grzasko N，et al. Oral ixazomib，lenalidomide，and dexamethasone for multiple myeloma [J]. N Engl J Med，2016，374（17）：1621-1634.
[17] Dimopoulos MA，Oriol A，Nahi H，et al. Daratuzumab，lenalidomide，and dexamethasone for multiple myeloma [J]. N Engl J Med，2016，375（14）：1319-1331.
[18] Lonial S，Dimopoulos M，Palumbo A，et al. Elotuzumab therapy for relapsed or refractory multiple myeloma [J]. N Engl J Med，2015，373（7）：621-631.
[19] 中国医师协会血液科医师分会，中华医学会血液学分会，中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南（2017年修订）[J].中华内科杂志，2017，56（11）：866-870.
[20] Anderson H，Scarffe JH，Ranson M，et al. VAD chemotherapy as remission induction for multiple myeloma [J]. Br J Cancer，1995，71（2）：326-330.
[21] Oken MM，Harrington DP，Abramson N，et al. Comparison of melphalan and prednisone with vincristine，carmustine，melphalan，cyclophosphamide，and prednisone in the treatment of multiple myeloma：results of Eastern Cooperative Oncology Group Study E2479 [J]. Cancer，1997， 79（8）：1561-1567.
[22] 王玉芬，徐文君，陈玉丽，等.BD方案联合环磷酰胺和吡柔比星治疗复发/难治性多发性骨髓瘤疗效观察[J].中国实验血液学杂志，2016，24（5）：1454-1458.
[23] 韩潇，白海，王存邦，等.BD和VAD-T方案治疗复发/难治性多发性骨髓瘤的临床疗效比较[J].现代肿瘤学，2016，24（21）：3466-3468.
[24] 李迎春，张嵘，王慧涵，等.沙利度胺联合环磷酰胺和地塞米松治疗复发难治性骨髓瘤[J].中国医科大学学报，2013，42（6）：564-566. |
|
|
|
